Mostrar el registro sencillo del ítem

dc.contributor.authorFlores Montero, Juan Alejandro 
dc.contributor.authorSanoja Flores, Luzalba
dc.contributor.authorPaiva, Bruno
dc.contributor.authorPuig Morón, Noemí
dc.contributor.authorGarcía Sánchez, Omar
dc.contributor.authorBöttcher, Sebastian
dc.contributor.authorvan der Velden, VHJ
dc.contributor.authorPérez Morán, José
dc.contributor.authorVidriales Vicente, María Belén 
dc.contributor.authorGarcía Sanz, Ramón 
dc.contributor.authorJiménez, C.
dc.contributor.authorGonzález Díaz, Marcos 
dc.contributor.authorMartínez-López, J.
dc.contributor.authorCorral-Mateos, A.
dc.contributor.authorGrigori, G.E.
dc.contributor.authorFluxá, R.
dc.contributor.authorPontes, R.
dc.contributor.authorCaetano, J.
dc.contributor.authorSedek, L.
dc.contributor.authorCañizo Fernández-Roldán, María Consuelo del
dc.contributor.authorBladé, Joan
dc.contributor.authorHuerta, Juan José la
dc.contributor.authorAguilar, Carlos
dc.contributor.authorBárez, Abelardo
dc.contributor.authorGarcía-Mateo, A.
dc.contributor.authorLabrador Gómez, Jorge
dc.contributor.authorLeoz, P.
dc.contributor.authorAguilera-Sanz, C.
dc.contributor.authorSan Miguel, Jesús F
dc.contributor.authorMateos Manteca, María Victoria 
dc.contributor.authorDurie, Brian
dc.contributor.authorvan Dongen, J.J.M.
dc.contributor.authorOrfao de Matos Correia e Vale, José Alberto 
dc.date.accessioned2018-02-06T08:06:44Z
dc.date.available2018-02-06T08:06:44Z
dc.date.issued2017-10
dc.identifier.citationLeukemia. 2017 Oct;31(10):2094-2103es_ES
dc.identifier.urihttp://hdl.handle.net/10366/136897
dc.description.abstract[EN]Flow cytometry has become a highly valuable method to monitor minimal residual disease (MRD) and evaluate the depth of complete response (CR) in bone marrow (BM) of multiple myeloma (MM) after therapy. However, current flow-MRD has lower sensitivity than molecular methods and lacks standardization. Here we report on a novel next generation flow (NGF) approach for highly sensitive and standardized MRD detection in MM. An optimized 2-tube 8-color antibody panel was constructed in five cycles of design-evaluation-redesign. In addition, a bulk-lysis procedure was established for acquisition of ⩾107 cells/sample, and novel software tools were constructed for automatic plasma cell gating. Multicenter evaluation of 110 follow-up BM from MM patients in very good partial response (VGPR) or CR showed a higher sensitivity for NGF-MRD vs conventional 8-color flow-MRD -MRD-positive rate of 47 vs 34% (P=0.003)-. Thus, 25% of patients classified as MRD-negative by conventional 8-color flow were MRD-positive by NGF, translating into a significantly longer progression-free survival for MRD-negative vs MRD-positive CR patients by NGF (75% progression-free survival not reached vs 7 months; P=0.02). This study establishes EuroFlow-based NGF as a highly sensitive, fully standardized approach for MRD detection in MM which overcomes the major limitations of conventional flow-MRD methods and is ready for implementation in routine diagnostics.es_ES
dc.description.sponsorshipThis work has been supported by the International Myeloma Foundation-Black Swan Research Initiative, the Red Temática de Investigación Cooperativa en Cáncer (RTICC); grant SA079U14 from the Consejería de Educación, Junta de Castilla y León, Valladolid, Spain and; grant DTS15/00119 from Instituto de Salud Carlos III, Ministerio de Economía y Competitividad, Madrid, Spain.es_ES
dc.format.mimetypeapplication/pdf
dc.language.isoenges_ES
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 Unported
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/3.0/
dc.subjectOncologyes_ES
dc.subjectNext generation flowes_ES
dc.subjectMultiple myelomaes_ES
dc.subjectMinimal residual diseasees_ES
dc.titleNext Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myelomaes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.identifier.doi10.1038/leu.2017.29
dc.relation.projectIDSA079U14 from the Consejería de Educación, Junta de Castilla y León, Valladolid, Spaines_ES
dc.relation.projectIDDTS15/00119 from Instituto de Salud Carlos III, Ministerio de Economía y Competitividad, Madrid, Spaines_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivs 3.0 Unported
Excepto si se señala otra cosa, la licencia del ítem se describe como Attribution-NonCommercial-NoDerivs 3.0 Unported